SCHEMBL1744324

SCHEMBL1744324

Cc1cc(OC/C=C(/c2ccc(Cl)cc2)c2ccc(I)cc2)ccc1OC(C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
HTR2B P41595 1/20 0.53
TDP1 Q9NUW8 1/20 0.43
PPARD Q03181 8/20 0.40
PPARG P37231 7/20 0.40
PPARA Q07869 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAP4K4 O95819 2/20 0.38
TRPM4 Q8TD43 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.37
PTGDR Q13258 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
ALOX12 P18054 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744326 1.00 TSHR (0.53) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL1747388 1.00 TSHR (0.53) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL2510139 0.92 PPARD (0.48) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL1745112 0.92 PPARD (0.48) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL2510142 0.92 PPARD (0.48) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL1746571 0.90 PPARD (0.48) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL1744420 0.90 PPARD (0.46) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL1745537 0.90 PPARD (0.48) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL1744421 0.90 PPARD (0.46) TSHRHTR2AHTR2CHTR2BTDP1
SCHEMBL1745535 0.90 PPARD (0.48) TSHRHTR2AHTR2CHTR2BTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386540-A1 Novel compounds, their preparation and use High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
US-20110245244-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2011-10-06 US disclosed
US-7943613-B2 Compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2011-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245244-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARG, PPARA, PPARD TSHR 1294/4885HTR2A 1310/4885HTR2C 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.